279 related articles for article (PubMed ID: 27310883)
1. Tacrolimus in Corticosteroid-Refractory Vernal Keratoconjunctivitis.
Chatterjee S; Agrawal D
Cornea; 2016 Nov; 35(11):1444-1448. PubMed ID: 27310883
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Effect of 0.1% Tacrolimus Eye Drops in the Tarsal Form of Vernal Keratoconjunctivitis.
Wan Q; Tang J; Han Y; Wang D; Ye H
Ophthalmic Res; 2018; 59(3):126-134. PubMed ID: 28803239
[TBL] [Abstract][Full Text] [Related]
3. A comparative study between ciclosporine A eye drop (2%) and tacrolimus eye ointment (0.03%) in management of children with refractory vernal keratoconjunctivitis.
Heikal MA; Soliman TT; Abousaif WS; Shebl AA
Graefes Arch Clin Exp Ophthalmol; 2022 Jan; 260(1):353-361. PubMed ID: 34453603
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus Ointment for Treatment of Vernal Keratoconjunctivitis.
Al-Amri AM; Mirza AG; Al-Hakami AM
Middle East Afr J Ophthalmol; 2016; 23(1):135-8. PubMed ID: 26957853
[TBL] [Abstract][Full Text] [Related]
5. Dermatologic tacrolimus ointment on the eyelids for steroid-refractory vernal keratoconjunctivitis.
Liu FY; Liu HY; Chu HS; Chen WL; Hu FR; Wang IJ
Graefes Arch Clin Exp Ophthalmol; 2019 May; 257(5):967-974. PubMed ID: 30852635
[TBL] [Abstract][Full Text] [Related]
6. Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study.
Attas-Fox L; Barkana Y; Iskhakov V; Rayvich S; Gerber Y; Morad Y; Avni I; Zadok D
Curr Eye Res; 2008 Jul; 33(7):545-9. PubMed ID: 18600486
[TBL] [Abstract][Full Text] [Related]
7. Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis.
Kheirkhah A; Zavareh MK; Farzbod F; Mahbod M; Behrouz MJ
Eye (Lond); 2011 Jul; 25(7):872-80. PubMed ID: 21475312
[TBL] [Abstract][Full Text] [Related]
8. Vernal keratoconjunctivitis in Thailand.
Kosrirukvongs P; Vichyanond P; Wongsawad W
Asian Pac J Allergy Immunol; 2003 Mar; 21(1):25-30. PubMed ID: 12931748
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial.
Müller EG; Santos MSD; Freitas D; Gomes JÁP; Belfort R
Arq Bras Oftalmol; 2017 Jun; 80(3):154-158. PubMed ID: 28832739
[TBL] [Abstract][Full Text] [Related]
10. A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children.
Labcharoenwongs P; Jirapongsananuruk O; Visitsunthorn N; Kosrirukvongs P; Saengin P; Vichyanond P
Asian Pac J Allergy Immunol; 2012 Sep; 30(3):177-84. PubMed ID: 23156846
[TBL] [Abstract][Full Text] [Related]
11. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis.
Ebihara N; Ohashi Y; Uchio E; Okamoto S; Kumagai N; Shoji J; Takamura E; Nakagawa Y; Nanba K; Fukushima A; Fujishima H
J Ocul Pharmacol Ther; 2009 Aug; 25(4):365-72. PubMed ID: 19441889
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of tacrolimus ointment for treatment of atopic keratoconjunctivitis.
Al-Amri AM
Am J Ophthalmol; 2014 Feb; 157(2):280-6. PubMed ID: 24439439
[TBL] [Abstract][Full Text] [Related]
13. Monotherapy of topical tacrolimus 0.03% in the treatment of vernal keratoconjunctivitis in the pediatric population.
Samyukta SK; Pawar N; Ravindran M; Allapitchai F; Rengappa R
J AAPOS; 2019 Feb; 23(1):36.e1-36.e5. PubMed ID: 30664932
[TBL] [Abstract][Full Text] [Related]
14. Steroid-Sparing Effect of 0.1% Tacrolimus Eye Drop for Treatment of Shield Ulcer and Corneal Epitheliopathy in Refractory Allergic Ocular Diseases.
Miyazaki D; Fukushima A; Ohashi Y; Ebihara N; Uchio E; Okamoto S; Shoji J; Takamura E; Nakagawa Y; Namba K; Fujishima H
Ophthalmology; 2017 Mar; 124(3):287-294. PubMed ID: 28017421
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of 2% Rebamipide Suspension for Vernal Keratoconjunctivitis: A Clinical Comparison with Topical Immune Modulators Cyclosporine and Tacrolimus.
Malhotra C; Singh H; Jain AK; Gupta A; Ram J
Ocul Immunol Inflamm; 2022 Jul; 30(5):1083-1091. PubMed ID: 33764241
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis.
Akpek EK; Dart JK; Watson S; Christen W; Dursun D; Yoo S; O'Brien TP; Schein OD; Gottsch JD
Ophthalmology; 2004 Mar; 111(3):476-82. PubMed ID: 15019322
[TBL] [Abstract][Full Text] [Related]
17. Topical ciclosporin in the treatment of vernal keratoconjunctivitis in Rwanda, Central Africa: a prospective, randomised, double-masked, controlled clinical trial.
De Smedt S; Nkurikiye J; Fonteyne Y; Tuft S; De Bacquer D; Gilbert C; Kestelyn P
Br J Ophthalmol; 2012 Mar; 96(3):323-8. PubMed ID: 22001151
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases.
Miyazaki D; Tominaga T; Kakimaru-Hasegawa A; Nagata Y; Hasegawa J; Inoue Y
Ophthalmology; 2008 Jun; 115(6):988-992.e5. PubMed ID: 17900694
[TBL] [Abstract][Full Text] [Related]
19. Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes.
Vichyanond P; Pacharn P; Pleyer U; Leonardi A
Pediatr Allergy Immunol; 2014 Jun; 25(4):314-22. PubMed ID: 24438133
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effect of 0.03% tacrolimus ointment for ocular graft versus host disease and vernal keratoconjunctivitis.
Ryu EH; Kim JM; Laddha PM; Chung ES; Chung TY
Korean J Ophthalmol; 2012 Aug; 26(4):241-7. PubMed ID: 22870021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
